Raymond W Lam, Sidney H Kennedy, Camelia Adams, Anees Bahji, Serge Beaulieu, Venkat Bhat, Pierre Blier, Daniel M Blumberger, Elisa Brietzke, Trisha Chakrabarty, André Do, Benicio N Frey, Peter Giacobbe, David Gratzer, Sophie Grigoriadis, Jeffrey Habert, M Ishrat Husain, Zahinoor Ismail, Alexander McGirr, Roger S McIntyre, Erin E Michalak, Daniel J Müller, Sagar V Parikh, Lena S Quilty, Arun V Ravindran, Nisha Ravindran, Johanne Renaud, Joshua D Rosenblat, Zainab Samaan, Gayatri Saraf, Kathryn Schade, Ayal Schaffer, Mark Sinyor, Claudio N Soares, Jennifer Swainson, Valerie H Taylor, Smadar V Tourjman, Rudolf Uher, Michael van Ameringen, Gustavo Vazquez, Simone Vigod, Daphne Voineskos, Lakshmi N Yatham, Roumen V Milev
{"title":"加拿大情绪与焦虑治疗网络 (CANMAT) 2023 年成人重度抑郁障碍管理临床指南更新：加拿大情绪与焦虑治疗网络 (CANMAT) 2023 年成人重度抑郁障碍管理临床指南更新。","authors":"Raymond W Lam, Sidney H Kennedy, Camelia Adams, Anees Bahji, Serge Beaulieu, Venkat Bhat, Pierre Blier, Daniel M Blumberger, Elisa Brietzke, Trisha Chakrabarty, André Do, Benicio N Frey, Peter Giacobbe, David Gratzer, Sophie Grigoriadis, Jeffrey Habert, M Ishrat Husain, Zahinoor Ismail, Alexander McGirr, Roger S McIntyre, Erin E Michalak, Daniel J Müller, Sagar V Parikh, Lena S Quilty, Arun V Ravindran, Nisha Ravindran, Johanne Renaud, Joshua D Rosenblat, Zainab Samaan, Gayatri Saraf, Kathryn Schade, Ayal Schaffer, Mark Sinyor, Claudio N Soares, Jennifer Swainson, Valerie H Taylor, Smadar V Tourjman, Rudolf Uher, Michael van Ameringen, Gustavo Vazquez, Simone Vigod, Daphne Voineskos, Lakshmi N Yatham, Roumen V Milev","doi":"10.1177/07067437241245384","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate new evidence and provide new and revised recommendations for the assessment and management of MDD in adults.</p><p><strong>Methods: </strong>CANMAT convened a guidelines editorial group comprised of academic clinicians and patient partners. A systematic literature review was conducted, focusing on systematic reviews and meta-analyses published since the 2016 guidelines. Recommendations were organized by lines of treatment, which were informed by CANMAT-defined levels of evidence and supplemented by clinical support (consisting of expert consensus on safety, tolerability, and feasibility). Drafts were revised based on review by patient partners, expert peer review, and a defined expert consensus process.</p><p><strong>Results: </strong>The updated guidelines comprise eight primary topics, in a question-and-answer format, that map a patient care journey from assessment to selection of evidence-based treatments, prevention of recurrence, and strategies for inadequate response. The guidelines adopt a personalized care approach that emphasizes shared decision-making that reflects the values, preferences, and treatment history of the patient with MDD. Tables provide new and updated recommendations for psychological, pharmacological, lifestyle, complementary and alternative medicine, digital health, and neuromodulation treatments. Caveats and limitations of the evidence are highlighted.</p><p><strong>Conclusions: </strong>The CANMAT 2023 updated guidelines provide evidence-informed recommendations for the management of MDD, in a clinician-friendly format. These updated guidelines emphasize a collaborative, personalized, and systematic management approach that will help optimize outcomes for adults with MDD.</p>","PeriodicalId":55283,"journal":{"name":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351064/pdf/","citationCount":"0","resultStr":"{\"title\":\"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.\",\"authors\":\"Raymond W Lam, Sidney H Kennedy, Camelia Adams, Anees Bahji, Serge Beaulieu, Venkat Bhat, Pierre Blier, Daniel M Blumberger, Elisa Brietzke, Trisha Chakrabarty, André Do, Benicio N Frey, Peter Giacobbe, David Gratzer, Sophie Grigoriadis, Jeffrey Habert, M Ishrat Husain, Zahinoor Ismail, Alexander McGirr, Roger S McIntyre, Erin E Michalak, Daniel J Müller, Sagar V Parikh, Lena S Quilty, Arun V Ravindran, Nisha Ravindran, Johanne Renaud, Joshua D Rosenblat, Zainab Samaan, Gayatri Saraf, Kathryn Schade, Ayal Schaffer, Mark Sinyor, Claudio N Soares, Jennifer Swainson, Valerie H Taylor, Smadar V Tourjman, Rudolf Uher, Michael van Ameringen, Gustavo Vazquez, Simone Vigod, Daphne Voineskos, Lakshmi N Yatham, Roumen V Milev\",\"doi\":\"10.1177/07067437241245384\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate new evidence and provide new and revised recommendations for the assessment and management of MDD in adults.</p><p><strong>Methods: </strong>CANMAT convened a guidelines editorial group comprised of academic clinicians and patient partners. A systematic literature review was conducted, focusing on systematic reviews and meta-analyses published since the 2016 guidelines. Recommendations were organized by lines of treatment, which were informed by CANMAT-defined levels of evidence and supplemented by clinical support (consisting of expert consensus on safety, tolerability, and feasibility). Drafts were revised based on review by patient partners, expert peer review, and a defined expert consensus process.</p><p><strong>Results: </strong>The updated guidelines comprise eight primary topics, in a question-and-answer format, that map a patient care journey from assessment to selection of evidence-based treatments, prevention of recurrence, and strategies for inadequate response. The guidelines adopt a personalized care approach that emphasizes shared decision-making that reflects the values, preferences, and treatment history of the patient with MDD. Tables provide new and updated recommendations for psychological, pharmacological, lifestyle, complementary and alternative medicine, digital health, and neuromodulation treatments. Caveats and limitations of the evidence are highlighted.</p><p><strong>Conclusions: </strong>The CANMAT 2023 updated guidelines provide evidence-informed recommendations for the management of MDD, in a clinician-friendly format. These updated guidelines emphasize a collaborative, personalized, and systematic management approach that will help optimize outcomes for adults with MDD.</p>\",\"PeriodicalId\":55283,\"journal\":{\"name\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351064/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/07067437241245384\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/07067437241245384","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate new evidence and provide new and revised recommendations for the assessment and management of MDD in adults.
Methods: CANMAT convened a guidelines editorial group comprised of academic clinicians and patient partners. A systematic literature review was conducted, focusing on systematic reviews and meta-analyses published since the 2016 guidelines. Recommendations were organized by lines of treatment, which were informed by CANMAT-defined levels of evidence and supplemented by clinical support (consisting of expert consensus on safety, tolerability, and feasibility). Drafts were revised based on review by patient partners, expert peer review, and a defined expert consensus process.
Results: The updated guidelines comprise eight primary topics, in a question-and-answer format, that map a patient care journey from assessment to selection of evidence-based treatments, prevention of recurrence, and strategies for inadequate response. The guidelines adopt a personalized care approach that emphasizes shared decision-making that reflects the values, preferences, and treatment history of the patient with MDD. Tables provide new and updated recommendations for psychological, pharmacological, lifestyle, complementary and alternative medicine, digital health, and neuromodulation treatments. Caveats and limitations of the evidence are highlighted.
Conclusions: The CANMAT 2023 updated guidelines provide evidence-informed recommendations for the management of MDD, in a clinician-friendly format. These updated guidelines emphasize a collaborative, personalized, and systematic management approach that will help optimize outcomes for adults with MDD.
期刊介绍：
Established in 1956, The Canadian Journal of Psychiatry (The CJP) has been keeping psychiatrists up-to-date on the latest research for nearly 60 years. The CJP provides a forum for psychiatry and mental health professionals to share their findings with researchers and clinicians. The CJP includes peer-reviewed scientific articles analyzing ongoing developments in Canadian and international psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
